Difference between revisions of "Nadofaragene firadenovec (Adstiladrin)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Bacillus Calmette-Guérin (BCG)" to "BCG vaccine") |
||
| (One intermediate revision by one other user not shown) | |||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *2022-12-16: Initial approval for adult patients with high-risk | + | *2022-12-16: Initial approval for adult patients with high-risk BCG vaccine unresponsive non-muscle invasive [[bladder cancer]] (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ''(Based on rAd-IFN-CS-003)'' |
==Also known as== | ==Also known as== | ||
| − | *'''Code name:''' SCH 721015 | + | *'''Code name:''' SCH-721015 |
*'''Generic name:''' nadofaragene firadenovec-vncg | *'''Generic name:''' nadofaragene firadenovec-vncg | ||
*'''Brand name:''' Adstiladrin, Instiladrin | *'''Brand name:''' Adstiladrin, Instiladrin | ||
Latest revision as of 17:14, 7 November 2023
General information
From the NCI Drug Dictionary: A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.
Diseases for which it is used
History of changes in FDA indication
- 2022-12-16: Initial approval for adult patients with high-risk BCG vaccine unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. (Based on rAd-IFN-CS-003)
Also known as
- Code name: SCH-721015
- Generic name: nadofaragene firadenovec-vncg
- Brand name: Adstiladrin, Instiladrin